Om

Freenome, Inc. is a biotechnology company specializing in blood-based early cancer detection. Using a comprehensive multiomics platform that integrates molecular biology, computational biology, and machine learning, Freenome develops noninvasive screening tests based on a routine blood draw. Its technology analyzes a wide range of circulating biomarkers, including cell-free DNA, RNA, proteins, and immune-related signals, to identify cancer at its earliest, most treatable stages. Freenome focuses on next-generation diagnostics for cancers such as colorectal and other solid tumors, serving healthcare providers, health systems, and population health decision-makers with tools designed to improve cancer screening and precision oncology workflows. The company also engages in clinical research programs to support development, discovery, and validation of single-cancer and multi-cancer tests. Founded in 2014 and headquartered in Brisbane, California, Freenome plays a notable role in the life sciences and healthcare sectors as a provider of advanced cancer detection solutions powered by AI-driven genomics and multiomics analysis.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I FREENOME MED ENDAVU: Køb Freenome ($FRNM) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Freenome, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.